GlassScriptPhysician profile
Alissa M Floman
NPI 1104145812
$2,521.98
in general payments reported to CMS, 2019-2025
26 companies · $615 in 2025
The $615 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $126 · 2021: $126 · 2022: $84.69 · 2023: $404 · 2024: $672 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.99 |
| Education | $103.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $463.35 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Abbvie INC. | $327.50 | 2019-2024 | |
| Millicent US INC | $253.51 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Mayne Pharma Commercial LLC | $178.45 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $139.58 | 2024-2025 | Myfembree |
| Allergan, INC. | $119.55 | 2019 | |
| Astellas Pharma US INC | $118.65 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $108.17 | 2019-2025 | |
| Therapeuticsmd, INC. | $98.37 | 2019-2020 | |
| Coopersurgical, INC. | $85.17 | 2019-2024 | Paragard T 380a |
| Pfizer INC. | $82.58 | 2024-2025 | |
| Organon LLC | $73.97 | 2023-2025 | Nexplanon |
| Aspira Women'S Health INC | $65.84 | 2024 | Ova1 |
| Channel Medsystems, INC. | $53.48 | 2021 | |
| Agile Therapeutics, INC. | $49.41 | 2022-2023 | Twirla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $46.60 | 2022-2025 | Slynd |
| Merck Sharp & Dohme LLC | $40.62 | 2019-2024 | Gardasil, Gardasil 9 |
| Amag Pharmaceuticals, INC. | $38.10 | 2019 | |
| Myriad Women'S Health, INC. | $37.33 | 2023 | Myrisk |
| Biogen, INC. | $27.88 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $25.83 | 2019 | |
| Solventum Corporation | $23.72 | 2025 | |
| Daiichi Sankyo INC. | $17.05 | 2019 | |
| Ethicon US, LLC | $17.03 | 2024 | Enseal X1 |
| Smith+Nephew, INC. | $16.56 | 2024 | Pico 7, Pico 14, Renasys Touch |
| Optumhealth Care Solutions, LLC | $13.68 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alissa Floman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.